In clinical trials on over 1000 elderly patients comparing the recombinant as compared to traditionally in hens’ eggs produced vaccine, no differences in immunogenicity and safety were observed.
Astellas press release, March 11, 2013
Astellas Pharma and UMN Pharma reports progress on phase III clinical trial of recombinant influenza HA vaccine ASP7374 manufactured with Baculovirus expression system